DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity

Tuberculosis

Volumn 86, Issue 5, 2006, Pages 374-381

  Shimizu, Yasuo ^a   Dobashi, Kunio ^b   Mita, Yoshihiro ^a   Endou, Katsuaki ^a   Moriya, Shogo ^c   Osano, Kaoru ^c   Koike, Yoko ^a   Higuchi, Seiichi ^a   Yabe, Shigeki ^a   Utsugi, Mitsuyoshi ^a   Ishizuka, Tamotsu ^a   Hisada, Takeshi ^a   Nakazawa, Tsugio ^b   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c Nisshinbo Industries Inc   (Japan)

Author keywords

Drug induced hepatotoxicity; N acetyltransferase 2; Pharmacogenomics; Tuberculosis

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYANAMIDE; DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; ISONIAZID; RIFAMPICIN; SILANE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CLONE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MICROARRAY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; HYBRIDIZATION; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG TUBERCULOSIS; MALE; OLIGONUCLEOTIDE PROBE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VALIDITY;

ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; ISONIAZID; JAPAN; LIVER DISEASES; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; TUBERCULOSIS, PULMONARY;

EID: 33746873652     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2005.09.002     Document Type: Article

References (11)

1. Frieden T.R., Sterling T.R., Munsiff S.S., Watt C.J., and Dye C. Tuberculosis. Lancet 362 (2003) 887-899
2. Gordin F., Chaisson R.E., Matts J.P., Miller C., de Lourdes Garcia M., Hafner R., et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 283 (2000) 1445-1450
3. Parkin D.P., Vandenplas S., Botha F.J., Vandenplas M.L., Seifart H.I., van Helden P.D., et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 155 (1997) 1717-1722
4. Ohno M., Yamaguchi I., Yamamoto I., Fukuda T., Yokota S., Maekura R., et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4 (2000) 256-261
5. Tomihata K., and Ikada Y. Crosslinking of hyaluronic acid with water-soluble carbodiimide. J Biomed Mater Res 37 (1997) 243-251
6. Kimura N., Oda R., Inaki Y., and Suzuki O. Attachment of oligonucleotide probes to poly carbodiimide-coated glass for microarray applications. Nucleic Acids Res 32 (2004) e68
7. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11 (1990) 272-276
8. Fretland A.J., Leff M.A., Doll M.A., and Hein D.W. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 11 (2001) 207-215
9. Hein D.W., Grant D.M., and Sim E. Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 10 (2000) 291-292
10. Sunaga N., Kohno T., Yanagitani N., Sugimura H., Kunitoh H., Tamura T., et al. Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidemiol Biomarkers Prev 11 (2002) 730-738
11. Huang Y.S., Chern H.D., Su W.J., Wu J.C., Lai S.L., Yang S.Y., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35 (2002) 883-889